A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion — Stella
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
United States
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida
Boston Medical Center /ID# 255066, Boston, Massachusetts
Mayo Clinic - Rochester /ID# 255258, Rochester, Minnesota
Icahn School of Medicine at Mount Sinai /ID# 255408, New York, New York
Columbia University Medical Center /ID# 255068, New York, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073, New York, New York
Atrium Health Levine Cancer Institute /ID# 255074, Charlotte, North Carolina
Atrium Health Wake Forest Baptist Medical Center /ID# 255851, Winston-Salem, North Carolina
Oregon Medical Research Center /ID# 255119, Portland, Oregon
University of Washington /ID# 261581, Seattle, Washington
Wisconsin Medical Center /ID# 255836, Milwaukee, Wisconsin
Australia
Westmead Hospital /ID# 255200, Westmead, New South Wales
Princess Alexandra Hospital /ID# 255202, Woolloongabba, Queensland